Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for Idiopathic Subglottic Stenosis
NCT07654517Phase 1Not yet recruiting
- Start
- Apr 2027
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic subglottic stenosis (ISS) comparing Pirfenidone with Placebo (2 arms). Primary endpoint: Proportion of participants with a moderate or worse (Grade ≥2) adverse event at 52 weeks. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
pirfenidone
03
Conditions
idiopathic subglottic stenosis (ISS)
Beyond the preview
Go deeper on NCT07654517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654517.